EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Fondaparinux Sodium: Recent Advances in the Management of Thrombosis

Rupert M Bauersachs iD

Journal of Cardiovascular Pharmacology and Therapeutics · 2023

DOI: 10.1177/10742484221145010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cardiovascular Pharmacology and Therapeutics, 2023. Verfasst von Rupert M Bauersachs. Beteiligte Einrichtung: Department of Angiology, Cardioangiologic Center Bethanien, Frankfurt, Germany. Hauptthemen laut MEDLINE: COVID-19, Thrombosis, Venous Thrombosis. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fondaparinux sodium is a chemically synthesized selective factor Xa inhibitor approved for the prevention and treatment of venous thromboembolic events, that is, deep vein thrombosis, pulmonary embolism, and superficial vein thrombosis, in acutely ill (including those affected by COVID-19 or cancer patients) and those undergoing surgeries. Since its approval in 2002, the efficacy and safety of fondaparinux is well demonstrated by many clinical studies, establishing the value of fondaparinux in clinical practice. Some of the advantages with fondaparinux are its chemical nature of synthesis, minimal risk of contamination, 100% absolute bioavailability subcutaneously, instant onset of action, a long half-life, direct renal excretion, fewer adverse reactions when compared with direct oral anticoagulants, and being an ideal alternative in conditions where oral anticoagulants are not approved for use or in patients intolerant to low molecular weight heparins (LMWH). In the last decade, the real-world use of fondaparinux has been explored in other conditions such as acute coronary syndromes, bariatric surgery, in patients developing vaccine-induced immune thrombotic thrombocytopenia (VITT) and in pregnant women with heparin-induced thrombocytopenia (HIT), or those intolerant to LMWH. The emerging data from these studies have culminated in recent updates in the guidelines that recommend the use of fondaparinux under various conditions. This paper aims to review the recent data and the subsequent updates in the recommendations of various guidelines on the use of fondaparinux sodium.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19ThrombosisVenous ThrombosisPregnancyHumansFemaleFondaparinuxHeparin, Low-Molecular-WeightPolysaccharidesAnticoagulantsHeparin

Stichwörter der Autor:innen

acute coronary syndromesanticoagulantbariatric surgerydeep vein thrombosisfondaparinux sodiumpregnancypulmonary embolismsuperficial vein thrombosisvenous thromboembolic events

Substanzen

FondaparinuxHeparin, Low-Molecular-WeightPolysaccharidesAnticoagulantsHeparin

Autor:innen und Institutionen

  • Department of Angiology, Cardioangiologic Center Bethanien, Frankfurt, Germany.
  • Center for Vascular Research, Munich, Germany.

ORCID-Profile: Rupert M Bauersachs

Zitieren

APA

Bauersachs, R. M. (2023). Fondaparinux Sodium: Recent Advances in the Management of Thrombosis. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/10742484221145010

Vancouver

Bauersachs RM. Fondaparinux Sodium: Recent Advances in the Management of Thrombosis. Journal of Cardiovascular Pharmacology and Therapeutics. 2023. doi:10.1177/10742484221145010

BibTeX
@article{Bauersachs2023,
  author = {Bauersachs, Rupert M},
  title = {Fondaparinux Sodium: Recent Advances in the Management of Thrombosis},
  journal = {Journal of Cardiovascular Pharmacology and Therapeutics},
  year = {2023},
  doi = {10.1177/10742484221145010}
}
Kostenlos starten →